Merck & Co., Inc. (MRK) and Serum Institute of India, Ltd. Announce Collaboration to Develop and Expand Global Access to Pneumococcal Conjugate Vaccine (PCV)
8/3/2011 8:01:24 AM
WHITEHOUSE STATION, N.J. & PUNE, India--(BUSINESS WIRE)--Merck (NYSE: MRK), known outside the United States and Canada as MSD, and Serum Institute of India Limited, an Indian company, announced today an agreement to work together to develop and commercialize a pneumococcal conjugate vaccine (PCV) for use in the emerging and developing world countries. It is estimated that one out of every two children immunized in the world is vaccinated by a vaccine manufactured by Serum Institute. In addition, Merck has developed more than one-third of the world's vaccines for children, adolescents and adults.
comments powered by